Amgen CEO sees his compensation spike; How junk food becomes addictive;

 @FiercePharma: Teva outgrows Big Pharma in IMS ranking. Report | Follow @FiercePharma

> Amgen CEO Kevin Sharer has experienced some ups and downs in recent years, but his salary has largely been headed up. His compensation spiked 11 percent last year, rising to $15.3 million despite slipping revenue numbers. Story

> Isotechnika Pharma says that the NDA for the company's next-generation calcineurin inhibitor, voclosporin, has been accepted by the FDA for priority review. The application was submitted by Isotechnika's partner, Lux Biosciences. Isotechnika release

> Pharming has increased its authorized share capital to 400 million shares from 200 million shares. Report

> Shares of Oxygen Biotherapeutics shot up Monday after it launched a new OTC skin cream earlier than expected. Story

And Finally... New research demonstrates how junk food works as an addictive drug, steadily raising the threshold on satisfaction and spurring people to eat far too much. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.